SUSAR

SUSAR - Axcellant

SUSAR

  1. lut 28, 2025

What Does the 'SUSAR’ Mean?

SUSAR stands for Suspected Unexpected Serious Adverse Reaction. It refers to an adverse event that occurs during a clinical trial which is both serious and unexpected, and is suspected to be related to the study drug or intervention.

SUSARs are a critical component of drug safety monitoring in clinical research. They require prompt reporting to regulatory authorities and ethics committees, as they may impact the overall safety profile of the investigational product and the conduct of the clinical trial.

Why Is the 'SUSAR’ Important in Clinical Research?

SUSARs play a crucial role in ensuring patient safety and maintaining the integrity of clinical trials. They serve as early warning signals for potential serious risks associated with investigational products, allowing researchers and regulatory bodies to take swift action to protect study participants and reassess the risk-benefit profile of the study.

The identification and reporting of SUSARs are essential for compliance with regulatory requirements and ethical standards in clinical research. Proper management of SUSARs contributes to the overall quality and reliability of clinical trial data, ultimately influencing decisions about drug development, approval, and post-marketing surveillance.

Good Practices and Procedures

  1. Implement a standardized SUSAR assessment process, including a causality evaluation tool and a decision tree for determining unexpectedness.
  2. Establish a dedicated SUSAR review committee comprising medical experts, safety officers, and regulatory specialists to ensure thorough evaluation and timely reporting.
  3. Develop and maintain a comprehensive SUSAR tracking database, integrating it with the clinical trial management system for efficient monitoring and trend analysis.
  4. Conduct regular SUSAR-focused training sessions for investigators and study staff, emphasizing the importance of prompt recognition and reporting of potential SUSARs.
  5. Perform periodic audits of the SUSAR management process to identify areas for improvement and ensure compliance with evolving regulatory requirements.

Related Terms

Read more

Axcellant partners with Prometheus MedTech.AI to accelerate AI-powered cardiac diagnostics

We’re pleased to announce a strategic partnership between Axcellant and Prometheus MedTech.AI — a medtech startup developing AI-powered solutions for…

Axcellant at EANM 2025: What We Brought Back from Barcelona

The Axcellant team has returned from the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona — and it’s…

Radioisotopes in Medicine: Clinical Applications, Safety, and Regulatory Considerations

The robust development of nuclear medicine depends on the availability of radioactive isotopes, some of which are used for diagnostic…